ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2592

The Effects of Early Life Trauma and Socioeconomic Position on Systemic Lupus Erythematosus Risk in Adulthood
Abstract Number: 1278

The Effects of Fatigue on Self-Reported Mental and Physical Health in Childhood-Onset Systemic Lupus Erythematosus: A Cross-Sectional Study
Abstract Number: 2085

The Effects of Pioglitazone on Metabolic Dysregulation in Inclusion Body Myositis: An Open-Label Pilot Study
Abstract Number: 0129

The Efficacy and Safety of Telitacicept Following Rituximab Immunotherapy on Antiphospholipid Syndrome, a Prospective 24- Week Study
Abstract Number: 0960

The Esophageal Epithelium in Systemic Sclerosis: Cellular and Molecular Dysregulation Revealed by Single-Cell RNA Sequencing
Abstract Number: 1672

The Evaluation of SLE Outcome Measures in Telemedicine
Abstract Number: 2186

The Exploration of Secondary Amplified Musculoskeletal Pain Syndrome (AMPS) in Pediatric Patients with Rheumatologic Disease
Abstract Number: 2682

The Forgotten Costs of SLE: Estimating Indirect Costs in a National SLE Cohort
Abstract Number: 1447

The Frequency of Diffuse Idiopathic Skeletal Hyperostosis (DISH) in Spondyloarthritis in Comparison to Age and Sex-matched Controls and Impact of SpA on Onset Age of DISH
Abstract Number: 0477

The Global Prevalence of Interstitial Lung Disease in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis
Abstract Number: 0097

The Human Lupus TREX1 D18N Mutation Engineered in C. Elegans Leads to Cell Death. What Can We Learn About Lupus Using C. Elegans?
Abstract Number: 2105

The Identity, Impact, and Management of OA and OA Pain from the Perspective of People with OA: A Systematic Literature Review of Qualitative Studies
Abstract Number: 1257

The Immune and Growth Characteristics of Children Born to Mothers with Systemic Lupus Erythematosus
Abstract Number: 1811

The Immune Map of Lupus Nephritis: A Spatially Resolved Kidney Proteomic Approach
Abstract Number: 2416

The Impact of Active Lupus Nephritis on Work Productivity in Patients from a Latin American Lupus Cohort

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].